Patent Law Weblog
recent posts
- Constellation Designs, LLC v. LG Electronics Inc. (Fed. Cir. 2026)
- Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2026)
- PTAB Reverses § 101 Rejection Where Examiner Failed to Follow the Office’s Own Guidance
- Collision Communications v. Samsung: What Good Did the Government’s Statement of Interest Do?
- United States Files Statement of Interest in Patent Infringement Proceedings
about
Month: March 2012
-
The Intellectual Property Owners Association (IPO) will offer a one-hour webinar entitled "Personalized Medicine after Prometheus: Exploring the Limits of Patent-Eligibility" on April 5, 2012 beginning at 2:00 pm (ET). A panel consisting of Patent Docs author Dr. Kevin Noonan of McDonnell Boehnen Hulbert & Berghoff; Jonathan Singer of Fish & Richardson, who has represented…
-
Law Seminars International (LSI) will be offering a one-hour analysis on "Mayo v. Prometheus" on April 9, 2012 from 2:30 – 3:30 pm (Eastern). Gregory A. Castanias of Jones Day will moderate a panel including Prof. Joshua D. Sarnoff, Associate Professor of Law at DePaul University College of Law, who will provide the Petitioner's perspective,…
-
By Donald Zuhn — PPH Pilot Program between USPTO and IMPI Extended On March 7th, the U.S. Patent and Trademark Office announced that the Office would be extending its Patent Prosecution Highway (PPH) pilot program with the Mexican Institute of Industrial Property (IMPI). The pilot program, which commended on March 1, 2011 (see "USPTO News…
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases. United Therapeutics Corp. v. Sandoz, Inc.3:12-cv-01617; filed March 14, 2012 in the District Court of New Jersey Infringement of U.S. Patent Nos. 5,153,222 ("Method of Treating Pulmonary Hypertension with Benzidine Prostaglandins," issued October 6, 1992),…
-
By Donald Zuhn — One day after the Supreme Court reversed the Federal Circuit in Mayo Collaborative Services v. Prometheus Laboratories, Inc., finding Prometheus' diagnostic method claims to be invalid for "effectively claim[ing] underlying laws of nature," the U.S. Patent and Trademark Office issued a memorandum to its examining corps providing the Office's preliminary guidance…
-
By Kevin E. Noonan — Perhaps unintentionally, the Supreme Court issued a challenge to America's patent attorneys in its Prometheus decision, warning against "interpreting patent statutes in ways that make patent eligibility 'depend simply on the draftsman's art.'" As purveyors of "the draftman's art," then it behooves us to ask whether claims perceived to be…
-
This morning, as expected, the Supreme Court issued an Order granting the petition for writ of certiorari in Association for Molecular Pathology v. Myriad, vacating the judgment, and remanding the case back to the Federal Circuit for further consideration in light of Mayo Collaborative Services v. Prometheus Laboratories. For additional information regarding this and other…
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases. AstraZeneca AB et al v. Mylan Laboratories Ltd. et al.1:12-cv-00300; filed March 12, 2012 in the District Court of Delaware • Plaintiffs: AstraZeneca AB; Aktiebolaget Hassle; Astrazeneca LP; KBI Inc.; KBI-E Inc.• Defendants: Mylan Laboratories…
-
March 26-27, 2012 – PTO Procedures under the America Invents Act*** (American Conference Institute) – New York, NY March 27, 2012 – The Biosimilar Drug Approval Pathway: Draft FDA Guidance and Beyond (McDonnell Boehnen Hulbert & Berghoff LLP) – 10:00 am to 11:15 am (CT) March 27, 2012 – US Patent Reform Forum 2012 (Managing…
-
Law Seminars International (LSI) will be offering a one-hour analysis on "New Best Practices for Patent Prosecution after the AIA" on March 29, 2012 beginning at 1:00 pm (Eastern). Paul R. Gupta of Orrick Herrington & Sutcliffe LLP will moderate a panel including Joseph C. Kirincich, the Director & Corporate Counsel for Avaya Inc. and…
Patent Docs 